METHOD FOR COMPLEX TREATMENT OF ENDOGENOUS UVEITIS FOLLOWED BY MACULAR EDEMA Russian patent published in 2017 - IPC A61N5/06 A61K31/167 A61K31/4425 A61K33/14 A61K35/16 A61K35/19 A61K38/08 A61K38/49 A61P27/02 A61M5/00 

FIELD: medicine.

SUBSTANCE: alternately, on the side of the affected eye, pterygopalatine and BTE drug injections are performed and ultraviolet irradiation of blood is performed. Pterygopalatine injections are performed by introducing platelet-enriched autoplasma at a dose of 3-5 ml by a course of 3-4 injections with an interval of 72-96 hours. BTE injections are performed by administering a drug mixture containing dalargin 1 mg, lidocaine 40 mg, mexidol 50 mg, gemaza 5000 ME. The course of treatment is 6-7 injections daily. In addition, an intravenous injection of ozonized saline with an ozone concentration of 400-800 mcg/l, volume of 150-200 ml, at a rate of 30-40 drops per minute, with a course of 6-7 injections, is performed daily.

EFFECT: persistent long-term clinical outcome, consisting in improved visual functions, increased visual acuity due to relief of inflammation in the uveal tract.

3 cl, 6 dwg, 3 ex